WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented in scientific sessions at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas, November 6–9.

“Up to 30% of Americans living with type 1 diabetes (T1D) are affected by chronic kidney disease (CKD),1,2 which puts them at significant risk for cardiovascular (CV) events and kidney failure despite current standard of care.3 No new treatments have been approved in CKD associated with T1D for more than 30 years,”3 said Carolina Aldworth, M.D., MSc, Executive Director, U.S. Medical Affairs at Bayer. “We are honored that the results of FINE-ONE will be featured at the opening plenary session at ASN, reflecting Bayer’s commitment to clinical research in another patient population with high unmet need.”